REHOVOT, Israel--(BUSINESS WIRE)--Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced today it hired ...

In an area in northern China, cancer in the cardia, which is located between the esophagus and the stomach, occurs at high rates, and the cancer type has distinct features compared to Western ...

Future Cardia, a medical device company, announced an expanded collaboration with remote cardiac monitoring company, Artella Solutions. Future Cardia is developing an implantable cardiac monitoring ...

Partnership leverages ARTELLA’S Active State Monitoring SaaS platform and Certified Independent Diagnostic Testing Facility (IDTF) with Future Cardia’s Implantable Cardiac Devices. The companies began ...

REHOVOT, Israel - Pi-Cardia Ltd. announced today that it successfully completed the First-in-Human (FIH) studies with its Leaflex™ Performer catheter. The Leaflex™ Performer is a trans-femoral ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Pi-Cardia received Food and Drug Administration clearance ...

Poor cardiovascular health (CVH) prior to pregnancy may be more of a marker of risk for subclinical atherosclerosis in midlife than adverse events occurring during pregnancy, such as gestational ...